4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $249,024 | -9.3% | 19,562 | +28.7% | 0.00% | 0.0% |
| Q2 2023 | $274,682 | +10.3% | 15,201 | +5.0% | 0.00% | 0.0% |
| Q1 2023 | $248,963 | -21.0% | 14,483 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $315,293 | +174.2% | 14,196 | -0.4% | 0.00% | +100.0% |
| Q3 2022 | $115,000 | +17.3% | 14,247 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $98,000 | -53.3% | 14,045 | +1.3% | 0.00% | 0.0% |
| Q1 2022 | $210,000 | -35.6% | 13,867 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $326,000 | +5.5% | 14,842 | +29.4% | 0.00% | 0.0% |
| Q3 2021 | $309,000 | +132.3% | 11,468 | +108.4% | 0.00% | – |
| Q2 2021 | $133,000 | -32.5% | 5,504 | +21.4% | 0.00% | -100.0% |
| Q1 2021 | $197,000 | – | 4,535 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |